Key Highlights

● Third-quarter results will carry $216 million of acquired R&D expense.

● The charge reduces earnings by $0.11 per diluted share.

● Full-year 2026 adjusted EPS guidance is now $13.76 to $13.96.

● The Apogee Therapeutics deal closed on September 3, 2026.

AbbVie Inc. (NYSE:ABBV), whose common stock trades on the New York Stock Exchange under the ticker ABBV, filed a Form 8-K dated 5 October 2026 that updated its earnings guidance ahead of the third-quarter report. The company said its results for the quarter ending 30 September 2026 will carry $216 million of pre-tax expense for acquired in-process research and development and milestones. AbbVie put the effect at $0.11 per diluted share, on both a GAAP and an adjusted basis.

The filing also set out revised figures. Adjusted diluted earnings per share for the third quarter are now guided at $3.73 to $3.77, while the full-year 2026 range is $13.76 to $13.96, in US dollars. AbbVie stressed that the third-quarter numbers are preliminary and remain subject to its financial statement closing procedures, so final results could differ.

Background: the July Outlook and the Apogee Deal

The new range follows a lower starting point than the one issued with second-quarter results on 31 July 2026. At that stage, AbbVie guided adjusted earnings of $13.87 to $14.07 per share, trimmed from $13.91 to $14.11. That earlier range reflected $0.14 of dilution from the proposed purchase of Apogee Therapeutics, partly offset by $0.10 of stronger underlying performance, and excluded research charges booked after the second quarter.

The Apogee transaction has since completed. According to AbbVie, it closed on 3 September 2026 at $135.11 per share in cash, an equity value of about $10.9 billion. The deal adds zumilokibart, an anti-IL-13 antibody being developed for atopic dermatitis, together with APG273 for asthma. AbbVie said then that the purchase should reduce 2026 adjusted earnings by $0.14 and 2027 earnings by about $0.46, with accretion not starting until 2032.

Operating Context from the Second Quarter

Historical results show why the research charge is a modest portion of the picture. For the second quarter of 2026, AbbVie reported net revenues of $16.990 billion, up 10.2 per cent as reported. Skyrizi contributed $5.505 billion and Rinvoq $2.525 billion, each up roughly 24 per cent. GAAP diluted earnings per share were $2.03, while the adjusted figure was $3.65, up 22.9 per cent on the prior year.

Those numbers describe the immunology franchise that supports the group while older products face competition. They are historical and do not by themselves indicate what the third quarter will show.

Why the Update Matters

AbbVie does not forecast acquired research expense, because the timing of licensing and acquisition deals is hard to predict. Each time a deal is struck, guidance therefore moves mechanically. The 5 October filing quantifies that effect for the quarter. Deducting $0.11 from both ends of the July range gives exactly $13.76 to $13.96, so the full-year change appears to be the charge alone.

Many consensus estimates were set before the Apogee closing.

Guidance Moves Mechanically Whenever AbbVie Books a Deal

The disclosure is quite narrow in scope. It covers one expense line and its effect on per-share earnings, and it does not give third-quarter revenue, product-level sales, cash flow or debt levels. The financing cost of the Apogee purchase, and any change in interest expense, will only become visible in the full quarterly accounts.

AbbVie will publish its third-quarter 2026 results before the market opens on Friday 30 October 2026, with a live webcast at 8:00 a.m. Central Time. That release should confirm the preliminary charge, update product sales and show whether management maintains the revised full-year range.